A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT ID: NCT06211764

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

272 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-09

Study Completion Date

2031-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Muscle Invasive Bladder Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: TAR-200

Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase.

Group Type EXPERIMENTAL

TAR-200

Intervention Type DRUG

Participants will receive TAR-200 intravesically.

Group B: Mitomycin C (MMC) or Gemcitabine

Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase.

Group Type ACTIVE_COMPARATOR

Mitomycin C

Intervention Type DRUG

Participants will receive MMC intravesically.

Gemcitabine

Intervention Type DRUG

Participants will receive gemcitabine intravesically.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAR-200

Participants will receive TAR-200 intravesically.

Intervention Type DRUG

Mitomycin C

Participants will receive MMC intravesically.

Intervention Type DRUG

Gemcitabine

Participants will receive gemcitabine intravesically.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JNJ-17000139

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis by local pathology (within 90 days of documented informed consent) of recurrent, papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) \[defined as high-grade Ta or any T1, no carcinoma in situ (CIS)\]
* Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial (transitional cell histology) predominance. However, neuroendocrine, and small cell variants will be excluded
* Participants must be ineligible for or have elected not to undergo Radical Cystectomy (RC)
* Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2

Exclusion Criteria

* Presence of CIS at any point from time of diagnosis of papillary-only HR-NMIBC recurrence to randomization. Additionally, presence or history of histologically confirmed, muscle-invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, T2, T3, T4, N+, and/or M+)
* Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200. Participants with tumors involving the prostatic urethra in men will be excluded
* A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (\>4000 mL)
* Indwelling catheters are not permitted; however, intermittent catheterization is acceptable
* Previous treatment with TAR-200
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Urology

Little Rock, Arkansas, United States

Site Status

Genesis Research LLC

Los Alamitos, California, United States

Site Status

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

Site Status

University of California Irvine Medical Center

Orange, California, United States

Site Status

University of California San Francisco

San Francisco, California, United States

Site Status

Genesis Research LLC

Torrance, California, United States

Site Status

Colorado Clinical Research

Lakewood, Colorado, United States

Site Status

Florida Urology Partners

Riverview, Florida, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

UroPartners

Chicago Ridge, Illinois, United States

Site Status

Urology of Indiana

Carmel, Indiana, United States

Site Status

First Urology, PSC

Jeffersonville, Indiana, United States

Site Status

Wichita Urology Group

Wichita, Kansas, United States

Site Status

Comprehensive Urology

Royal Oak, Michigan, United States

Site Status

Specialty Clinical Research of St Louis

St Louis, Missouri, United States

Site Status

Associated Medical Professionals

Syracuse, New York, United States

Site Status

The Urology Group

Cincinnati, Ohio, United States

Site Status

Central Ohio Urology Group

Gahanna, Ohio, United States

Site Status

Centers for Advanced Urology LLC d b a MidLantic Urology

Bala-Cynwyd, Pennsylvania, United States

Site Status

Ralph H. Johnson Veterans Affairs Medical Center

Charleston, South Carolina, United States

Site Status

Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States

Site Status

Low Country Urology Clinics

North Charleston, South Carolina, United States

Site Status

Urology Associates

Nashville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Urology Austin

Austin, Texas, United States

Site Status

Urology Clinics of North Texas

Dallas, Texas, United States

Site Status

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Site Status

Houston Metro Urology

Houston, Texas, United States

Site Status

Spokane Urology

Spokane, Washington, United States

Site Status

Clinica Santa Isabel

Buenos Aires, , Argentina

Site Status

Investigaciones Clinico Moleculares (ICM)

CABA, , Argentina

Site Status

Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

Córdoba, , Argentina

Site Status

Centro Urologico Profesor Bengio

Córdoba, , Argentina

Site Status

Hospital Privado de la Comunidad

Mar del Plata, , Argentina

Site Status

AZ Sint-Jan

Bruges, , Belgium

Site Status

Cliniques Universitaires Saint Luc

Brussels, , Belgium

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

Algemeen ziekenhuis Maria Middelares

Ghent, , Belgium

Site Status

Algemeen Ziekenhuis Delta

Roeselare, , Belgium

Site Status

Fundacao Pio XII

Barretos, , Brazil

Site Status

NAIC Nair Antunes Instituto do Cancer

Bauru, , Brazil

Site Status

Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP

Campinas, , Brazil

Site Status

Liga Paranaense de Combate ao Cancer

Curitiba, , Brazil

Site Status

Irmandade Santa Casa de Misericordia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Hospital da Bahia

Salvador, , Brazil

Site Status

Sociedade Beneficente de Senhoras Hospital Sirio Libanes

São Paulo, , Brazil

Site Status

Real e Benemérita Associação Portuguesa de Beneficência

São Paulo, , Brazil

Site Status

Fundacao Antonio Prudente A C Camargo Cancer Center

São Paulo, , Brazil

Site Status

Peking University First Hospital

Beijing, , China

Site Status

West China School of Medicine/West China Hospital, Sichuan University

Cheng Du Shi, , China

Site Status

Chongqing Cancer Hospital

Chongqing, , China

Site Status

Sun Yat Sen University Cancer Center

Guangzhou, , China

Site Status

Shengjing Hospital Of China Medical University

Shenyang, , China

Site Status

Tianjin Medical University Cancer Institute and Hospital

Tianjin, , China

Site Status

The Second Hospital Of Tianjin Medical University

Tianjin, , China

Site Status

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, , China

Site Status

Tongji Medical College of Huazhong University Science Technology of Medicine Health Management

Wuhan, , China

Site Status

Xi an Jiaotong University Hospital

Xi'an, , China

Site Status

Hopital Claude Huriez

Lille, , France

Site Status

Polyclinique de Limoges - Francois Chenieux

Limoges, , France

Site Status

Institut Paoli Calmettes

Marseille, , France

Site Status

APHP - Hopital Bichat - Claude Bernard

Paris, , France

Site Status

Clinique de la Croix du Sud

Quint-Fonsegrives, , France

Site Status

Chu Rennes Hopital Pontchaillou

Rennes, , France

Site Status

Hopital Foch

Suresnes, , France

Site Status

Universitaetsklinikum Koeln

Cologne, , Germany

Site Status

Universitaetsklinikum Halle Saale

Halle, , Germany

Site Status

Klinikum Leverkusen gGmbH

Leverkusen, , Germany

Site Status

Universitatsklinikum Schleswig Holstein Campus Lubeck

Lübeck, , Germany

Site Status

Urologie Neandertal Praxis Mettmann

Mettmann, , Germany

Site Status

Klinikum der Universitaet Muenchen

München, , Germany

Site Status

Ospedale San Donato

Arezzo, , Italy

Site Status

Ospedale Provinciale di Macerata

Macerata, , Italy

Site Status

San Raffaele Hospital

Milan, , Italy

Site Status

Istituto Dei Tumori Di Milano

Milan, , Italy

Site Status

Ospedale S. Maria Delle Croci

Ravenna, , Italy

Site Status

Universita Campus Bio-Medico di Roma

Roma, , Italy

Site Status

Istituto Nazionale Tumori Regina Elena

Roma, , Italy

Site Status

Istituto Clinico Humanitas

Rozzano, , Italy

Site Status

PO Molinette Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino

Torino, , Italy

Site Status

Funabashi Municipal Medical Center

Funabashi Shi, , Japan

Site Status

Hakodate Goryoukaku Hospital

Hakodate, , Japan

Site Status

Hyogo Prefectural Amagasaki General Medical Center

Hyōgo, , Japan

Site Status

Niigata Cancer Center Hospital

Niigata, , Japan

Site Status

National Hospital Organization Okayama Medical Center

Okayama, , Japan

Site Status

Toho University Sakura Medical Center

Sakura, , Japan

Site Status

Toranomon Hospital

Tokyo, , Japan

Site Status

Yokohama City University Medical Center

Yokohama, , Japan

Site Status

Uniwersytecki Szpital Kliniczny w Bialymstoku

Bialystok, , Poland

Site Status

IN VIVO Sp. z o.o

Bydgoszcz, , Poland

Site Status

Szpital Uniwersytecki w Krakowie

Krakow, , Poland

Site Status

Uniwersytecki Szpital Kliniczny nr 4

Lublin, , Poland

Site Status

Wojewodzki Szpital im Sw Ojca Pio w Przemyslu

Przemyśl, , Poland

Site Status

Szpital Wojewodzki im Sw Lukasza SP ZOZ

Tarnów, , Poland

Site Status

MICS Centrum Medyczne Torun

Torun, , Poland

Site Status

Mazowiecki Szpital Onkologiczny

Wieliszew, , Poland

Site Status

Dolnoslaskie Centrum Onkologii

Wroclaw, , Poland

Site Status

Centrul Medical Unirea SRL

Brasov, , Romania

Site Status

Ponderas Academic Hospital

Bucharest, , Romania

Site Status

Institutul Oncologic Ion Chiricuta

Cluj-Napoca, , Romania

Site Status

Regina Maria

Cluj-Napoca, , Romania

Site Status

Spitalul Clinic Judetean de Urgenta Pius Brinzeu

Timișoara, , Romania

Site Status

Chungbuk National University Hospital

Chungcheongbuk Do, , South Korea

Site Status

Keimyung University Dongsan Hospital

Daegu, , South Korea

Site Status

National Cancer Center

Gyeonggi-do, , South Korea

Site Status

Chonnam National University Hwasun Hospital

Jeollanam-do, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul St Mary s Hospital

Seoul, , South Korea

Site Status

Pusan National University Yangsan Hospital

Yangsan, , South Korea

Site Status

Hosp. Univ. Germans Trias I Pujol

Badalona, , Spain

Site Status

Fund. Puigvert

Barcelona, , Spain

Site Status

Hosp. Gral. Univ. Gregorio Maranon

Madrid, , Spain

Site Status

Hosp. Univ. 12 de Octubre

Madrid, , Spain

Site Status

Hosp Virgen de La Victoria

Málaga, , Spain

Site Status

Hosp.Univ.Parc Tauli

Sabadell, , Spain

Site Status

Hosp. Univ. Marques de Valdecilla

Santander, , Spain

Site Status

Hosp. Virgen Del Rocio

Seville, , Spain

Site Status

Hosp. Clinico Univ. de Valencia

Valencia, , Spain

Site Status

St Bartholomews Hospital

London, , United Kingdom

Site Status

Salford Royal Hospital

Salford, , United Kingdom

Site Status

Southampton University Hospital

Southampton, , United Kingdom

Site Status

Lister Hospital

Stevenage, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Brazil China France Germany Italy Japan Poland Romania South Korea Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17000139BLC3004

Identifier Type: OTHER

Identifier Source: secondary_id

2023-507685-10-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

17000139BLC3004

Identifier Type: -

Identifier Source: org_study_id